MGMT and glioblastoma: For newly diagnosed GBM, alkylating agents are a mainstay option irrespective of the MGMT methylation status [30]; for elderly patients, those with MGMT methylation may have a greater benefit from TMZ monotherapy than radiotherapy [31], while those without methylation may not benefit from alklylating agents.